Pharmacogenomics and stratified health care ensure that healthcare professionals offer the ‘right treatment, for the right person, at the right time’ and is a fast developing area.
The aim of this module is to provide a comprehensive overview of the analytical strategies and techniques used in pharmacogenomics and explore some of the challenges and limitations in this field (e.g. availability of patient material for studies of adverse drug reactions which tend to be rare, allelic heterogeneity between different ethnic groups, patient compliance etc.). Biomarkers are the predictive tools for optimising drug response and preventing adverse drug reactions thus this module will also provide an overview of the different type of genomic biomarkers currently in use or emerging.
Outline Of Syllabus
- Genomic basis of: drug reaction, drug efficacy, ethnic differences in both these; and how these are applied in prescribing practice
- Use of genomic information, for targeted drug development
- Companion diagnostics and options for NHS service delivery models
- Different types and examples of genomic-targeted intervention (examples of genomically-targeted clinical, therapeutic or lifestyle choices)
- Genomic biomarkers: SNPs, variability of short sequence repeats, haplotypes, DNA modifications, e.g. methylation, deletions or insertions, copy number variants, RNA expression levels, RNA splicing, microRNA levels
- Use of biomarkers in treatments other than cancer